Grant: Engage Grants Program
McMaster University
$25,000.00
Achieving Thermal Stability for PnuVax's Protein-Conjugate Vaccines****
FY 2018-19
Summary
PnuVax Incorporated is dedicated to the production of high-quality vaccines and biopharmaceuticals for the promotion of public health worldwide. PnuVax produces several vaccines, including the protein/conjugates Prevnarr used to prevent pneumonia. The ability to produce and formulate this vaccine in a form that can be distributed without the need for refrigeration would provide a strong competitive advantage to PnuVax in this massive market - even small gains in market share would result in very large revenue increases. Improved thermal stability remains one of the largest unsolved problems in vaccinology. Recently, Dr. Filipe's group (Department of Chemical Engineering, McMaster University) has established a new method to thermally stabilize various complex biological agents such as enzymes, nucleic acids, cells and phage They demonstrated that a mixture of pullulan and trehalose results in the formation of water-soluble films (PT films) that can thermally stabilize these complex biological agents when incorporated into the mixture and dried as a film. We will apply this technology to a pneumococcal conjugate vaccine, Prevnarr 13, which will be supplied by PnuVax, our industrial partner for this project and determine the effectiveness of PT films to protect the vaccines agains thermal degradation. *Being able to thermally stabilize vaccines would greatly decrease the cost of vaccination, which would increase the number of people that can be vaccinated every year and would give a competitive advantage to a Canadian company in this highly competitive global market. An increase in the number of vaccine dosages produced in Ontario will also result in the creation of new jobs, especially those where highly qualified personal are needed. This project has the potential to have a strong local impact in terms of economic growth as well as globally, by making vaccines more accessible to people around the world.*
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
537729-2018
Name nom
Filipe, Carlos
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
1
Application title
Achieving Thermal Stability for PnuVax's Protein-Conjugate Vaccines****
Keyword
NSERC
Application summary
PnuVax Incorporated is dedicated to the production of high-quality vaccines and biopharmaceuticals for the promotion of public health worldwide. PnuVax produces several vaccines, including the protein/conjugates Prevnarr used to prevent pneumonia. The ability to produce and formulate this vaccine in a form that can be distributed without the need for refrigeration would provide a strong competitive advantage to PnuVax in this massive market - even small gains in market share would result in very large revenue increases. Improved thermal stability remains one of the largest unsolved problems in vaccinology. Recently, Dr. Filipe's group (Department of Chemical Engineering, McMaster University) has established a new method to thermally stabilize various complex biological agents such as enzymes, nucleic acids, cells and phage They demonstrated that a mixture of pullulan and trehalose results in the formation of water-soluble films (PT films) that can thermally stabilize these complex biological agents when incorporated into the mixture and dried as a film. We will apply this technology to a pneumococcal conjugate vaccine, Prevnarr 13, which will be supplied by PnuVax, our industrial partner for this project and determine the effectiveness of PT films to protect the vaccines agains thermal degradation. *Being able to thermally stabilize vaccines would greatly decrease the cost of vaccination, which would increase the number of people that can be vaccinated every year and would give a competitive advantage to a Canadian company in this highly competitive global market. An increase in the number of vaccine dosages produced in Ontario will also result in the creation of new jobs, especially those where highly qualified personal are needed. This project has the potential to have a strong local impact in terms of economic growth as well as globally, by making vaccines more accessible to people around the world.*